Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
Sell
23
TEVA Quote, Financials, Valuation and Earnings
Last price:
$15.08
Seasonality move
:
2.82%
Day range:
$14.87 - $15.50
52-week range:
$12.51 - $22.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.03x
P/B ratio:
3.22x
Volume:
7.8M
Avg. volume:
11.7M
1-year change:
6.87%
Market cap:
$17.3B
Revenue:
$16.5B
EPS (TTM):
-$1.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries
|
$4.1B | $0.70 | 4.3% | 71.31% | $23.26 |
|
ABBV
AbbVie
|
$14.8B | $2.12 | 5.05% | 227.63% | $211.73 |
|
ALVO
Alvotech
|
$98M | -$0.03 | 181.33% | -97.76% | $18.50 |
|
GSK
GSK PLC
|
$9.6B | $0.49 | 4.35% | 57.14% | $43.42 |
|
MRK
Merck &
|
$15.5B | $1.67 | -1.15% | 13.5% | $112.07 |
|
PFE
Pfizer
|
$17.3B | $0.46 | -3.03% | 29.69% | $31.26 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries
|
$15.08 | $23.26 | $17.3B | -- | $0.00 | 0% | 1.03x |
|
ABBV
AbbVie
|
$205.29 | $211.73 | $362.4B | 85.54x | $1.64 | 3.06% | 6.46x |
|
ALVO
Alvotech
|
$9.55 | $18.50 | $2.9B | -- | $0.00 | 0% | 5.20x |
|
GSK
GSK PLC
|
$38.74 | $43.42 | $78.9B | 24.47x | $0.40 | 4.01% | 2.00x |
|
MRK
Merck &
|
$89.23 | $112.07 | $225.4B | 13.26x | $0.81 | 3.54% | 3.53x |
|
PFE
Pfizer
|
$25.21 | $31.26 | $142.9B | 17.88x | $0.43 | 6.7% | 2.26x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries
|
76.8% | -0.891 | 70.19% | 0.50x |
|
ABBV
AbbVie
|
95.28% | -0.007 | 22.34% | 0.43x |
|
ALVO
Alvotech
|
162.94% | -2.628 | 26.79% | 1.44x |
|
GSK
GSK PLC
|
53.74% | 0.176 | 29.19% | 0.49x |
|
MRK
Merck &
|
44.49% | 0.543 | 15.58% | 0.84x |
|
PFE
Pfizer
|
41.92% | 0.618 | 43.87% | 0.82x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries
|
$2.1B | $922M | -6.34% | -23.87% | -0.19% | $446M |
|
ABBV
AbbVie
|
$10.7B | $84M | 5.68% | 61.64% | -10.38% | $6.8B |
|
ALVO
Alvotech
|
$70.9M | $13.5M | -54.24% | -- | 13.92% | -$70.3M |
|
GSK
GSK PLC
|
$7.1B | $2.8B | 8.51% | 19.22% | 8.71% | $1.5B |
|
MRK
Merck &
|
$11.8B | $4.3B | 21.67% | 40.25% | 28.79% | $2.5B |
|
PFE
Pfizer
|
$11.9B | $3.2B | 5.09% | 8.91% | 4.1% | $5.8B |
Teva Pharmaceutical Industries vs. Competitors
-
Which has Higher Returns TEVA or ABBV?
AbbVie has a net margin of -5.13% compared to Teva Pharmaceutical Industries's net margin of -0.15%. Teva Pharmaceutical Industries's return on equity of -23.87% beat AbbVie's return on equity of 61.64%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries50.15% -$0.19 $23.5B ABBVAbbVie70.89% -$0.02 $70.5B -
What do Analysts Say About TEVA or ABBV?
Teva Pharmaceutical Industries has a consensus price target of $23.26, signalling upside risk potential of 54.24%. On the other hand AbbVie has an analysts' consensus of $211.73 which suggests that it could grow by 3.14%. Given that Teva Pharmaceutical Industries has higher upside potential than AbbVie, analysts believe Teva Pharmaceutical Industries is more attractive than AbbVie.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries6 3 0 ABBVAbbVie11 10 0 -
Is TEVA or ABBV More Risky?
Teva Pharmaceutical Industries has a beta of 0.824, which suggesting that the stock is 17.586% less volatile than S&P 500. In comparison AbbVie has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.616%.
-
Which is a Better Dividend Stock TEVA or ABBV?
Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie offers a yield of 3.06% to investors and pays a quarterly dividend of $1.64 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. AbbVie pays out 257.71% of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or ABBV?
Teva Pharmaceutical Industries quarterly revenues are $4.2B, which are smaller than AbbVie quarterly revenues of $15.1B. Teva Pharmaceutical Industries's net income of -$217M is lower than AbbVie's net income of -$22M. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while AbbVie's PE ratio is 85.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.03x versus 6.46x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries1.03x -- $4.2B -$217M ABBVAbbVie6.46x 85.54x $15.1B -$22M
-
Which has Higher Returns TEVA or ALVO?
Alvotech has a net margin of -5.13% compared to Teva Pharmaceutical Industries's net margin of -44.29%. Teva Pharmaceutical Industries's return on equity of -23.87% beat Alvotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries50.15% -$0.19 $23.5B ALVOAlvotech46.87% -$0.24 $655.8M -
What do Analysts Say About TEVA or ALVO?
Teva Pharmaceutical Industries has a consensus price target of $23.26, signalling upside risk potential of 54.24%. On the other hand Alvotech has an analysts' consensus of $18.50 which suggests that it could grow by 93.72%. Given that Alvotech has higher upside potential than Teva Pharmaceutical Industries, analysts believe Alvotech is more attractive than Teva Pharmaceutical Industries.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries6 3 0 ALVOAlvotech2 2 0 -
Is TEVA or ALVO More Risky?
Teva Pharmaceutical Industries has a beta of 0.824, which suggesting that the stock is 17.586% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TEVA or ALVO?
Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or ALVO?
Teva Pharmaceutical Industries quarterly revenues are $4.2B, which are larger than Alvotech quarterly revenues of $151.2M. Teva Pharmaceutical Industries's net income of -$217M is lower than Alvotech's net income of -$67M. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Alvotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.03x versus 5.20x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries1.03x -- $4.2B -$217M ALVOAlvotech5.20x -- $151.2M -$67M
-
Which has Higher Returns TEVA or GSK?
GSK PLC has a net margin of -5.13% compared to Teva Pharmaceutical Industries's net margin of 5.1%. Teva Pharmaceutical Industries's return on equity of -23.87% beat GSK PLC's return on equity of 19.22%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries50.15% -$0.19 $23.5B GSKGSK PLC68.47% $0.26 $36.4B -
What do Analysts Say About TEVA or GSK?
Teva Pharmaceutical Industries has a consensus price target of $23.26, signalling upside risk potential of 54.24%. On the other hand GSK PLC has an analysts' consensus of $43.42 which suggests that it could grow by 12.08%. Given that Teva Pharmaceutical Industries has higher upside potential than GSK PLC, analysts believe Teva Pharmaceutical Industries is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries6 3 0 GSKGSK PLC2 3 1 -
Is TEVA or GSK More Risky?
Teva Pharmaceutical Industries has a beta of 0.824, which suggesting that the stock is 17.586% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.601, suggesting its less volatile than the S&P 500 by 39.914%.
-
Which is a Better Dividend Stock TEVA or GSK?
Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GSK PLC offers a yield of 4.01% to investors and pays a quarterly dividend of $0.40 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TEVA or GSK?
Teva Pharmaceutical Industries quarterly revenues are $4.2B, which are smaller than GSK PLC quarterly revenues of $10.4B. Teva Pharmaceutical Industries's net income of -$217M is lower than GSK PLC's net income of $530.1M. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while GSK PLC's PE ratio is 24.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.03x versus 2.00x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries1.03x -- $4.2B -$217M GSKGSK PLC2.00x 24.47x $10.4B $530.1M
-
Which has Higher Returns TEVA or MRK?
Merck & has a net margin of -5.13% compared to Teva Pharmaceutical Industries's net margin of 23.96%. Teva Pharmaceutical Industries's return on equity of -23.87% beat Merck &'s return on equity of 40.25%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries50.15% -$0.19 $23.5B MRKMerck &75.5% $1.48 $83.5B -
What do Analysts Say About TEVA or MRK?
Teva Pharmaceutical Industries has a consensus price target of $23.26, signalling upside risk potential of 54.24%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 25.59%. Given that Teva Pharmaceutical Industries has higher upside potential than Merck &, analysts believe Teva Pharmaceutical Industries is more attractive than Merck &.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries6 3 0 MRKMerck &11 10 0 -
Is TEVA or MRK More Risky?
Teva Pharmaceutical Industries has a beta of 0.824, which suggesting that the stock is 17.586% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.
-
Which is a Better Dividend Stock TEVA or MRK?
Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.54% to investors and pays a quarterly dividend of $0.81 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TEVA or MRK?
Teva Pharmaceutical Industries quarterly revenues are $4.2B, which are smaller than Merck & quarterly revenues of $15.6B. Teva Pharmaceutical Industries's net income of -$217M is lower than Merck &'s net income of $3.7B. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Merck &'s PE ratio is 13.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.03x versus 3.53x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries1.03x -- $4.2B -$217M MRKMerck &3.53x 13.26x $15.6B $3.7B
-
Which has Higher Returns TEVA or PFE?
Pfizer has a net margin of -5.13% compared to Teva Pharmaceutical Industries's net margin of 2.31%. Teva Pharmaceutical Industries's return on equity of -23.87% beat Pfizer's return on equity of 8.91%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries50.15% -$0.19 $23.5B PFEPfizer66.74% $0.07 $152.1B -
What do Analysts Say About TEVA or PFE?
Teva Pharmaceutical Industries has a consensus price target of $23.26, signalling upside risk potential of 54.24%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 23.99%. Given that Teva Pharmaceutical Industries has higher upside potential than Pfizer, analysts believe Teva Pharmaceutical Industries is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries6 3 0 PFEPfizer6 13 1 -
Is TEVA or PFE More Risky?
Teva Pharmaceutical Industries has a beta of 0.824, which suggesting that the stock is 17.586% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.
-
Which is a Better Dividend Stock TEVA or PFE?
Teva Pharmaceutical Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.7% to investors and pays a quarterly dividend of $0.43 per share. Teva Pharmaceutical Industries pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or PFE?
Teva Pharmaceutical Industries quarterly revenues are $4.2B, which are smaller than Pfizer quarterly revenues of $17.8B. Teva Pharmaceutical Industries's net income of -$217M is lower than Pfizer's net income of $410M. Notably, Teva Pharmaceutical Industries's price-to-earnings ratio is -- while Pfizer's PE ratio is 17.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries is 1.03x versus 2.26x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries1.03x -- $4.2B -$217M PFEPfizer2.26x 17.88x $17.8B $410M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
